
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc. is advancing its pipeline of innovative therapies, particularly highlighting the potential of ARV-806, which has exhibited over 40 times greater potency in reducing KRAS G12D protein compared to existing clinical degraders, positioning it advantageously in the competitive landscape. The company’s proprietary PROTAC technology showcases significant improvements in both efficacy and safety profiles, evidenced by favorable results in larger patient populations compared to comparable therapies. Additionally, the ability of certain candidates to synergize with PD-1 blockade and promote immune memory indicates promising potential for enhanced antitumor immunity, which may lead to successful clinical outcomes and bolster the company's long-term growth trajectory.
Bears say
Arvinas Inc's financial outlook appears negative primarily due to significant revenue reductions projected for its product vepdeg, which has been downgraded to a peak revenue estimate of $296.9 million by 2035, substantially lower than the previously anticipated $641.2 million. Additionally, the company's inability to access capital may hinder critical operations, potentially delaying profitability and cash flow generation. Moreover, recent data indicates a decline in the overall response rate for their therapy candidates in pancreatic cancer, which could undermine market confidence and negatively impact financial performance.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares